Moderna (NASDAQ:MRNA), an mRNA medicines and preventive vaccine developer, closed at $202.63, down 17.57%. Reports of a possible leak of late-stage personalized melanoma vaccine data sent shares lower today. Investors are waiting for the planned full Phase 3 presentation and Oct. 24 ESMO (European Society for Medical Oncology) data. Trading volume reached 49.3M shares, coming in about 148% above its three-month average of 19.9M shares. Moderna IPO'd in 2018 and has grown 989% since going public. The S&P 500 (SNPINDEX:^GSPC) fell 1.22% to 7,663, and the Nasdaq Composite (NASDAQINDEX:^IXIC) lost 2.60% to 26,009. Among biotechnology peers, BioNTech (NASDAQ:BNTX) closed at $89.67, down 1.77%, while Novavax (NASDAQ:NVAX) closed at $9.99, down 9.26%. Trading in MRNA shares was briefly halted today after reports of a partial data leak involving its personalized cancer vaccine hit the market. The leaked data supposedly showed that Moderna's intismeran autogene, when paired with Merck's (NYSE:MRK) immunotherapy Keytruda, "reduced the risk of recurrence or death in certain melanoma patients by 42% compared with Keytruda alone." This figure was lower than the Phase II results, which showed a 49% decline.
CryptoAlerta — análise de criptomoedas e mercado em tempo real